department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Zyloprim · pharmadog

pharmadog
drugs
Zyloprim

drug

patient view →

allopurinol

Marketedupdated 2mo ago

by Casper Pharma LLC

Approved

community read0 votes

indications

investigational

Duchenne Muscular Dystrophy

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Zyloprim

generic

allopurinol

indication

Kidney Disease (Nephropathy)

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 26, 2028

~2.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (16)

Feb 29, 2032compositionUS 8546436
Feb 29, 2032compositionUS 8546436
Dec 28, 2031method-of-use (U-2104)US 9956205
Dec 28, 2031method-of-use (U-2104)US 9956205
Aug 1, 2031method-of-use (U-2104)US 9216179
Aug 1, 2031method-of-use (U-2104)US 9216179
Dec 22, 2029formulationUS 83577133.5y
Dec 22, 2029formulationUS 83577133.5y
Aug 17, 2029method-of-use (U-2104)US 80844833.1y
Aug 17, 2029method-of-use (U-2104)US 80844833.1y
Apr 29, 2029method-of-use (U-2104)US 85464372.8y
Apr 29, 2029method-of-use (U-2104)US 85464372.8y
Nov 26, 2028method-of-use (U-2104)US 101830122.4y
Nov 26, 2028method-of-use (U-2104)US 101830122.4y
Nov 26, 2028method-of-use (U-2104)US 82833692.4y
Nov 26, 2028method-of-use (U-2104)US 82833692.4y

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 6

tagApproval18 co-mentions · 9 sources
drug(allopurinol + L-citrulline)9 co-mentions · 9 sources
drugAloprim9 co-mentions · 9 sources
drugAllorin9 co-mentions · 9 sources
tagSmall Molecule5 co-mentions · 5 sources
drugALLOPURINOL SODIUM4 co-mentions · 4 sources

Trials studying allopurinol

phase3A Study of Dotinurad Versus Allopurinol in Participants With Goutrecruitingn=500
phase3A Study of Dotinurad Versus Allopurinol in Tophaceous Goutrecruitingn=250
phase1Drug-Drug Interaction Study of ABP-671 in Gout Patientsrecruitingn=20
phase2Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)recruitingn=60
phase3Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Goutcompletedn=300
phase3Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patientscompletedn=2,202
phase3Extension Study of ABP-671 in Participants With Goutterminatedn=43
phase2Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphomaterminatedn=178

more trials →